Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.40 |
| ▸ | BTK | Q06187 | 5/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | CD69 | Q07108 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | TEC | P42680 | 1/20 | 0.37 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12396330 | 0.91 | EGFR (0.48) | EGFRBTKMAP4K1 | |
| SCHEMBL12371165 | 0.88 | EGFR (0.40) | EGFRBTKJAK3CD69SRC | |
| SCHEMBL12371159 | 0.85 | EGFR (0.43) | EGFRBTKJAK3 | |
| SCHEMBL12371144 | 0.85 | EGFR (0.56) | EGFRBTKJAK3CD69 | |
| SCHEMBL12371162 | 0.84 | BTK (0.47) | EGFRBTKJAK3CD69SRC | |
| SCHEMBL12371136 | 0.83 | EGFR (0.39) | EGFRBTKJAK3MAP4K1 | |
| SCHEMBL12396345 | 0.82 | EGFR (0.40) | EGFRBTKJAK3CD69 | |
| SCHEMBL12396278 | 0.80 | EGFR (0.48) | EGFRBTKJAK3 | |
| SCHEMBL12371157 | 0.79 | EGFR (0.43) | EGFRBTKJAK3CD69SRC | |
| SCHEMBL12371148 | 0.79 | EGFR (0.47) | EGFRBTKJAK3CD69SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879028-B2 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20140011810-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | EGFR, ERBB2, BRCA1 | EGFR 1/4885BTK 147/4885JAK3 254/4885 |
| US-20140011810-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | EGFR, ERBB2, BRCA1 | EGFR 1/4885BTK 147/4885JAK3 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.